- Home
- FISI vs SEPN Comparison
FISI vs SEPN Comparison
Compare FISI & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- SEPN
- Stock Information
- Founded
- FISI 1817
- SEPN 2022
- Country
- FISI United States
- SEPN United States
- Employees
- FISI 598
- SEPN N/A
- Industry
- FISI Major Banks
- SEPN
- Sector
- FISI Finance
- SEPN
- Exchange
- FISI Nasdaq
- SEPN NYSE
- Market Cap
- FISI 538.9M
- SEPN 522.7M
- IPO Year
- FISI 1999
- SEPN 2024
- Fundamental
- Price
- FISI $27.47
- SEPN $12.36
- Analyst Decision
- FISI Buy
- SEPN Strong Buy
- Analyst Count
- FISI 3
- SEPN 5
- Target Price
- FISI $33.00
- SEPN $26.75
- AVG Volume (30 Days)
- FISI 169.9K
- SEPN 345.7K
- Earning Date
- FISI 07-24-2025
- SEPN 08-15-2025
- Dividend Yield
- FISI 4.55%
- SEPN N/A
- EPS Growth
- FISI N/A
- SEPN N/A
- EPS
- FISI N/A
- SEPN N/A
- Revenue
- FISI $108,628,000.00
- SEPN $977,000.00
- Revenue This Year
- FISI $122.14
- SEPN $3,429.67
- Revenue Next Year
- FISI $5.87
- SEPN N/A
- P/E Ratio
- FISI N/A
- SEPN N/A
- Revenue Growth
- FISI N/A
- SEPN 108.76
- 52 Week Low
- FISI $20.97
- SEPN $4.17
- 52 Week High
- FISI $29.79
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- FISI 60.22
- SEPN N/A
- Support Level
- FISI $26.60
- SEPN N/A
- Resistance Level
- FISI $27.61
- SEPN N/A
- Average True Range (ATR)
- FISI 0.57
- SEPN 0.00
- MACD
- FISI 0.02
- SEPN 0.00
- Stochastic Oscillator
- FISI 77.42
- SEPN 0.00
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.